Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT04353492
What this trial is testing

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 562
Post-approval studies (Phase 4)Study completedNCT03440736
What this trial is testing

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

Who this might be right for
PsoriasisMetabolic Syndrome
Novartis Pharmaceuticals 781
Large-scale testing (Phase 3)Study completedNCT02315872
What this trial is testing

ACTH for Fatigue in Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Providence Health & Services 8
Not applicableStudy completedNCT03562975
What this trial is testing

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Who this might be right for
Multiple SclerosisPathologic ProcessesDemyelinating Diseases+5 more
University of South Florida 18
Testing effectiveness (Phase 2)Study completedNCT02484430
What this trial is testing

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative+3 more
National Cancer Institute (NCI) 16
Large-scale testing (Phase 3)WithdrawnNCT04531865
What this trial is testing

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Who this might be right for
Frequently Relapsing Nephrotic SyndromeSteroid-Dependent Nephrotic Syndrome
Children's Hospital of Fudan University
Post-approval studies (Phase 4)Study completedNCT00753792
What this trial is testing

Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

Who this might be right for
Multiple Sclerosis
Germans Trias i Pujol Hospital 49
Testing effectiveness (Phase 2)Study completedNCT01068392
What this trial is testing

Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Who this might be right for
B-cell Lymphomas
Dong-A University Hospital 42
Early research (Phase 1)Ended earlyNCT05289492
What this trial is testing

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iTeos Therapeutics 16
Not applicableEnded earlyNCT03777410
What this trial is testing

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Travera Inc 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT04124497
What this trial is testing

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaDeletion 17P Syndrome
Fondazione EMN Italy Onlus 45
Testing effectiveness (Phase 2)Study completedNCT00065260
What this trial is testing

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Who this might be right for
Aplastic Anemia
National Heart, Lung, and Blood Institute (NHLBI) 54
Not applicableUnknownNCT06205823
What this trial is testing

Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM

Who this might be right for
Myeloma Multiple
Seoul St. Mary's Hospital 1,600
Early research (Phase 1)Study completedNCT03915379
What this trial is testing

JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Janssen Research & Development, LLC 68
Early research (Phase 1)Study completedNCT02222688
What this trial is testing

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Thomas Kipps 26
Testing effectiveness (Phase 2)Looking for participantsNCT05789303
What this trial is testing

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple Myeloma
University of Chicago 83
Early research (Phase 1)Study completedNCT00554827
What this trial is testing

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Who this might be right for
Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc. 55
Early research (Phase 1)Looking for participantsNCT04024761
What this trial is testing

Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm+1 more
Dana-Farber Cancer Institute 50
Large-scale testing (Phase 3)Study completedNCT00958568
What this trial is testing

A Study in Relapse Prevention of Treatment-Resistant Depression

Who this might be right for
Treatment Resistant Depression
Eli Lilly and Company 892
Testing effectiveness (Phase 2)Study completedNCT02771197
What this trial is testing

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Who this might be right for
Acute Myeloid Leukemia
Northside Hospital, Inc. 20
Next Page